Kangchen Pharmaceutical's latest announcement: As of the end of October, it has repurchased 1.42% of its shares

Kangchen Pharmaceutical announced that as of October 31, 2021, the company has repurchased 2,273,523 shares through centralized auction transactions, accounting for 1.42% of the company's total share capital, the highest transaction price is 37.87 yuan / share, the lowest transaction price is 31.46 yuan / share, and the total amount paid is 79.3085 million yuan.

Kangchen Pharmaceutical's 2021 third quarter report shows that the company's main revenue was 597 million yuan, up 8.47% year-on-year; net profit attributable to the mother was 137 million yuan, down 3.2% year-on-year; deducted non-net profit of 120 million yuan, down 1.44% year-on-year; among them, in the third quarter of 2021, the company's single-quarter main revenue was 141 million yuan, down 30.18%; single-quarter net profit attributable to the mother was 37.1953 million yuan, down 3.89% year-on-year In the single quarter, the non-net profit was 33.0293 million yuan, down 0.59% year-on-year; the debt ratio was 6.04%, the investment income was 6.6257 million yuan, the financial expense was -17.9088 million yuan, and the gross profit margin was 86.88%.

In the past 90 days, a total of 3 institutions have given ratings and 3 buy ratings; the Securities Star Valuation Analysis Tool shows that Kangchen Pharmaceutical (603590) has a good company rating of 2.5 stars, a good price rating of 3 stars, and a valuation comprehensive rating of 2.5 stars.

The chairman of the company is Wang Xijuan. Ms. Wang Xijuan, Chairman, born in March 1961, Chinese nationality, no right of permanent residence abroad, doctoral degree, major in medicine and philosophy, senior engineer. Ms. Wang Xijuan has won the "First Prize of Scientific Progress of the All-China Federation of Industry and Commerce", "The Title of Top Ten Emerging Figures in the Most Influential List of China's Pharmaceutical Industry in 2013", "The Honorary Title of Beijing March 8th Red Flag Medal" and other honors. Ms. Wang Xijuan has served as a technician at Beijing Post and Telecommunications Hospital, the general manager of Beijing Weilun Pharmaceutical Development Company, and the chairman of Beijing Rongsheng Pharmaceutical Technology Co., Ltd.; He currently serves as the chairman of Kangchen Pharmaceutical, the director of Liaoning Kangchen, the chairman of Muren Investment, the executive director and manager of Kangchen Technology, the person in charge of the Pharmaceutical Research Institute, and the director of Sinopharm Kangchen. He has been a director of the company since 2003 and the chairman of the board of directors since December 2013.

This article is compiled by the Securities Star Data Center based on publicly available data and does not constitute investment opinions or suggestions, if there are any problems in the text, please contact us.